KTOV > Patent news: Kitov Announces Issuance of U.S. Patent Securing Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA
8 hours 59 minutes ago - DJNF
TEL-AVIV, Israel, August 10, 2016 /PRNewswire/ --
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that the United States Patent and Trademark Office (USPTO) issued patent # 9,408,837 covering Kitov's lead drug candidate KIT-302 which the Company expects to submit for a New Drug Application to the U.S. Food and Drug Administration by the end of 2016.
The patent, entitled "Ameliorating Drug-Induced Elevations In Blood Pressure By Adjunctive Use Of Antihypertensive Drugs," was issued on August 9, 2016 and will have a term that can extend to May 22, 2029. Kitov Pharmaceuticals is pursuing additional claims to inventions described in the U.S. Patent #9,408,837.
KIT-302 simultaneously treats pain caused by osteoarthritis and treats hypertension, which is a common side effect of certain stand-alone drugs that treat osteoarthritis pain. KIT-302 is comprised of two U.S. FDA approved drugs, celecoxib (the active ingredient in Pfizer's Celebrex(R)), for the treatment of pain caused by osteoarthritis and amlodipine besylate, a drug designed to treat hypertension.
"We are pleased with this newly granted patent for claims in connection with our KIT-302, representing a significant achievement for Kitov's combination drug developments," said J. Paul Waymack, MD the Chairman of the Board of Directors and Chief Medical Officer of Kitov. "We are committed to further developing the patent holdings over our proprietary assets in order to maximize value to our shareholders."
DUKE BASKETBALL and NOTRE DAME FOOTBALL
